Fig. 1From: RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAVTrial schema. Patients with resectable adenocarcinoma of the gastroesophageal junction are randomized to either receive 4 cycle of neoadjuvant FLOT chemotherapy (control arm) or 2 cycles of neoadjuvant FLOT induction chemotherapy followed by neoadjuvant chemoradiation (experimental arm) to 45 Gy with concurrent 5-FU/oxaliplatin-based chemotherapy, both followed by oncological resection and completion of chemotherapy with four further cycles of FLOTBack to article page